Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Contract terminated with Site Management Organization
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This observational, prospective, open-label, multi-center study will evaluate the effectiveness in disease reduction and the safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Data will be collected for 11 months.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort | Cohort |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Mean change in Disease Activity Score 28 (DAS28) | 11 months |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients with a change in Disease Activity Score 28 (DAS28) | 5 months | |
| European League Against Rheumatism (EULAR) response rates | 20 weeks | |
| Proportion of patients with disease remission |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with rheumatoid arthritis receiving RoActemra/Actemra
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bucharest | 020983 | Romania |
Not provided
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 20 weeks |
| Proportion of patients with low disease activity | 20 weeks |
| Incidence of adverse events | 11 months |
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |